THE EFFECT OF COMBINED CHEMOTHERAPY WITH PEMETREXED AND CISPLATIN ON T LYMPHOCYTE SUBSETS AND NK CELLS IN THE PERIPHERAL BLOOD OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER(GRANDULAR CANCER)

Objective To explore the effect of combined chemotherapy with pemetrexed and cisplatin on immunity of patients with Advanced non - small - cell lung cancer(NSCLC).Methods 40 patients with advanced gland -type NSCLC confirmed by the cellular or tissue pathologies received combined use of pemetrexed of 500mg /m2 on 1st day and cisplatin.and cisplatin of 75mg /m2 on 1st to d 3rd days for 21 days as a course.Before and after the consecutive therapy course,peripherial blood was collected from normal persons and patients.Flow cytometry was employed to detect the expression levels of CD~(3+),CD~(4+),CD~(8+) T lymphocytes and NK cells.Results Compared with the control group,the treatment group got decreased expression levels of CD~(3+),CD~(4+) T lymphocytes,CD~(4+)/CD~(8+) ratio and NK cells but increased level of CD~(8+) T lymphocyte was observed in advanced gland -type NSCLC patients before and after treatment(P 0.05).While after being treated with this chemotherapy regimen,increased levels of CD~(3+),CD~(4+) T lyrn- phocytes,CD~(4+)/CD~(8+) ratio and NK cells but decreased level of CD~(8+) T lymphocyte were observed in the patients(P 0.05).Conclusion Combined Chemotherapy with pemetrexed and cisplatin can enhance the cellular immune function of advanced gland -type NSCLC patients.The cellular immune function can be used as a prognostic indicator of the patients.